Alcohol or other CNS depressants
May result in increased CNS depression and may precipitate dystonic reactions.
May reduce therapeutic effects of prochlorperazine and worsen anticholinergic effects.
Frequency and severity of neuromuscular excitation and hypotension may be increased.
May result in increased plasma levels of beta-blocker and prochlorperazine.
The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.
Hypotensive action of guanethidine may be inhibited.
Possibility of seizure may be increased when subarachnoid metrizamide injection is used.
Plasma levels of prochlorperazine may be elevated, increasing the risk of adverse reactions.